Tositumomab
Title: Tositumomab
CAS Registry Number: 208921-02-2
CAS Name: Anti-(human CD20 antigen) immunoglobulin G2a (mouse monoclonal clone B1R1 g2a-chain) disulfide with mouse monoclonal clone B1R1 lx-chain, dimer
Additional Names: anti-B1 antibody
Literature References: Murine monoclonal antibody targeted against CD-20 antigen located on mature B lymphocytes but not on normal stem cells or progenitor cells. 131Iodine radioimmunoconjugate designed for tumor-targeted treatment of non-Hodgkin's lymphoma (NHL). Prepn: M. S. Kaminski et al., US 5595721 (1997 to Coulter); and clinical evaluation: idem et al., N. Engl. J. Med. 329, 459 (1993). Clinical study of radioimmunotherapy in NHL: eidem, Blood 96, 1259 (2000). Review of mechanism of action and clinical application: A. K. Gopal, O. W. Press, J. Lab. Clin. Med. 134, 445 (1999); of use in follicular lymphoma: A. J. Davies, Expert Opin. Biol. Ther. 5, 577-588 (2005).
 
Derivative Type: 131I-Labeled form
CAS Registry Number: 192391-48-3
Manufacturers' Codes: SB-393229
Trademarks: Bexxar (Coulter)
 
Therap-Cat: Antineoplastic.

Others monographs:
TosufloxacinAmicoumacin ACastor Oil, HydrogenatedClocortolone
AngiogeninGalegineZipeprolPygeum Africanum Extract
DeferasiroxPiperilatePleconarilThallium Sulfate
RupatadineSuet, PreparedAzimsulfuronPalitantin
©2016 DrugLead US FDA&EMEA